Author

N. M. A. Okba

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 1 Assay:imaging· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

B. L. Haagmans· 4 shared M. M. Lamers· 3 shared A. Z. Mykytyn· 2 shared B. Haagmans· 2 shared B. Rockx· 2 shared C. Wang· 2 shared D. de Meulder· 2 shared D. Drabek· 2 shared

Activity by Year

2020-2021 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

B. L. Haagmans

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

A. Tscherne, J. H. Schwarz, C. Rohde, A. Kupke, G. Kalodimou, L. Limpinsel, N. M. A. Okba, B. Bosnjak, I. Sandrock, S. Halwe, L. Sauerhering, K. Printz, L. Nan, E. Duell, S. Jany, , A. Volz

This paper describes the preclinical evaluation of MVA-SARS-2-S, a vector vaccine against SARS-CoV-2, showing it induces immune responses and protects mice from infection.

bioRxiv · Jan 9, 2021Microbiology

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

P. J. M. Brouwer, M. Brinkkemper, P. Maisonnasse, N. Dereuddre-Bosquet, M. Grobben, M. Claireaux, M. de Gast, R. Marlin, V. Chesnais, S. Diry, J. D. Allen, Y. Watanabe, J. M. Griezen, G. Kerster, H. L. Turner, , de Bree

This paper develops a two-component spike nanoparticle vaccine that protects macaques from SARS-CoV-2 infection by inducing strong neutralizing antibodies and reducing viral replication.

bioRxiv · Nov 7, 2020Immunology

Susceptibility of rabbits to SARS-CoV-2

A. Z. Mykytyn, M. M. Lamers, N. M. A. Okba, T. I. Breugem, D. Schipper, P. B. van den Doel, P. van Run, G. van Amerongen, L. de Waal, M. Koopmans, K. J. Stittelaar, J. van den Brand, B. L. Haagmans

This study shows rabbits can be infected with SARS-CoV-2 and shed infectious virus from the nose and throat.

bioRxiv · Aug 27, 2020Microbiology

SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model

B. L. Haagmans, D. Noack, N. M. A. Okba, W. LI, C. Wang, T. Bestebroer, R. de Vries, S. Herfst, D. de Meulder, P. van Run, M. M. Lamers, B. Rijnders, C. Rokx, F. J. M. van Kuppeveld, F. Grosveld, , B. Rockx

This study shows that high-dose convalescent plasma or monoclonal antibodies protect hamsters from SARS-CoV-2-induced lower respiratory disease, but lower doses are ineffective.

bioRxiv · Aug 24, 2020Microbiology

SARS-CoV-2 is transmitted via contact and via the air between ferrets.

M. Richard, A. Kok, D. de Meulder, T. M. Bestebroer, M. M. Lamers, N. M. A. Okba, M. Fentener van Vlissingen, B. Rockx, B. L. Haagmans, M. P. G. Koopmans, R. A. M. Fouchier, S. Herfst

This study shows SARS-CoV-2 spreads via direct contact and air between ferrets, supporting social distancing measures.

bioRxiv · Apr 16, 2020Microbiology

A human monoclonal 1 antibody blocking SARS-CoV-2 infection

C. Wang, W. Li, D. Drabek, N. M. A. Okba, R. van Haperen, A. D. M. E. Osterhaus, F. J. M. van Kuppeveld, B. L. Haagmans, F. Grosveld, B.-J. Bosch

This paper reports a human monoclonal antibody that neutralizes SARS-CoV-2 and SARS-CoV, targeting a shared epitope for potential prevention and treatment of COVID-19.

bioRxiv · Mar 11, 2020Microbiology